Mr. Silverman has served on the board of directors and executive of major multinational beverage corporations.
Mr. Silverman is the former Executive Vice President of Seagram’s global emerging markets division where he oversaw the growth of Seagram’s International Inc. Mr. Silverman was also a long-term strategic advisor at John Labatt Ltd. where he concentrated on optimization of operations and corporate structure. John Labatt was later sold to Interbrew Belgium in 1995, which later merged with AmBev to form InBev in 2004. Anheuser-Busch InBev (AB InBev) later consolidated with SABMiller in 2016, in a merger valued at over US $100 billion. Anheuser-Busch InBev SA/NV is now the largest alcohol based beverage brand manufacturing and marketing company in the world and is publicly traded as “BUD” on the New York Stock Exchange.
Mr. Silverman also served as a member of the Executive Committee of Bavaria Colombia with leading brands in their respective markets across Latin America. Mr. Silverman simultaneously served as the Executive Vice President and Chief Operations Officer of Bavaria Colombia Inc. Mr. Silverman planned and led the reorganization and restructuring and streamlining Bavaria thereby significantly increasing annual EBITDA, on efficiency.
During his tenure as EVP/COO at Bavaria, Jon and his operations team led the increase of per capita consumption of core beverage products, while maintaining in-market share of core brands – in excess of 95%. Bavaria was later sold to SABMiller in 2005 for US $7.8 billion, the largest investment by a foreign buyer in Colombia at that time, and a deal that enabled SAB Miller to become a major player in the Latin American beverage market. Bavaria is a known beer brand, but also marketed non-alcoholic food and beverages, including juices, water, and soft drinks.
Post his tenure at Seagram’s and Labatt, Mr. Silverman was focused on building accretive shareholder value through corporate planning and selecting assets for merger and acquisition. Jon’s consulting clients have included; Allied Lyons, Scott Paper, PepsiCo., Manufacturers Hanover/Morgan/Chase Bank, Mechanical Plastics, etc.
“We are honoured to have Mr. Silverman help guide our corporate development strategies,” said Phivida Chief Executive Officer John David Belfontaine. “Jon’s depth of experience and breadth of network makes him the ideal incumbent Chairman of the Phivida Advisory Board. Moreover, Jon shares our passion for getting Phivida branded cannabinoid infusions onto store shelves around the world, and for making a real difference in people’s lives.”
In a community context, Mr. Silverman served as both Vice Chair and Chairman on the board of directors at United Hospital over a span of fifteen years. Mr. Silverman was born in Montreal and maintains his Canadian citizenship, and has earned a Bachelor of Commerce from McGill University and an MBA from Cornell University.
“I am proud to join the Phivida Advisory Board,” said Mr. Silverman. “I was drawn to Phivida because of its high-quality executive and operations teams demonstrating; competence, vision, ethics and drive and passion. Clearly, cannabinoid-infused beverages, foods and supplements provide significant growth opportunity for major alcohol, and non-alcohol related food and beverage companies. Growing brands like Phivida are nimble in this burgeoning space, and are built to innovate quickly and efficiently, making Phivida a potential sector catalyst for larger companies looking to develop cannabinoid infused portfolios through collaboration and consolidation.”
Phivida has officially listed and is now trading on the Canadian Securities Exchange under the CSE ticker symbol “VIDA.” For investor information please e-mail all requests to IR@phivida.com or via the contact details below.
Phivida [“fiii-vee-daa”] is a publicly traded company listed on the Canadian Securities Exchange under the ticker symbol “VIDA” and in the United States as “PHVAF”. Phivida is a premiere brand of cannabidiol (“CBD”) infused functional foods, beverages and clinical health products, poised for global distribution.
Using nanoencapsulation technology, Phivida converts lipid based cannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida’s nanoencapsulated CBD is infused into CBD beverages, foods and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases.
Phivida Nutrition (a wholly owned subsidiary of Phivida Holdings Inc.), is the cannabinoid infused functional foods and beverage division sold under the brand name “Phivida”. The Phivida label cannabinoid infused beverage products target daily preventative health and enhanced performance, and include; CBD-Iced Teas, CBD Vitamin Juices and Shots, and CBD-Vegan Nutritional Shakes with up to 25mg of CBD in every bottle.
Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium cannabinoid infused foods, beverages and clinical products, with a dedicated to research, education and investing back into communities that we so proudly serve.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).